Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:TAOX

Synaptogenix Q2 2025 Earnings Results & Report

Synaptogenix logo
$3.50 -0.18 (-4.76%)
As of 02:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Synaptogenix reported Q2 2025 earnings on August 15, 2025. The company reported EPS of -$11.26.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

Synaptogenix EPS Results

Actual EPS
-$11.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Synaptogenix Q2 2025 Earnings FAQ

Synaptogenix (NASDAQ:TAOX) reported earnings of -$11.26 per share for Q2 2025. The report was announced on Friday, August 15, 2025.

Synaptogenix Earnings Headlines

Synaptogenix (NASDAQ:TAOX) & Otsuka (OTCMKTS:OTSKY) Critical Contrast
October 12 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109745
Comparing Innoviva (NASDAQ:INVA) and Synaptogenix (NASDAQ:TAOX)
October 11 at 10:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31108255
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.tc pixel
October 14 at 1:00 AM  |  Weiss Ratings (Ad)
Synaptogenix (NASDAQ:TAOX) Cut to Sell at Wall Street Zen
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083604
TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor
July 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-appoints-bittensor-investor-and-author-mark-jeffrey-as-advisor-302820337.html
TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI
June 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-set-to-join-the-russell-microcap-index-as-a-leading-public-gateway-to-decentralized-ai-302801330.html
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:TAOX) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and disorders involving memory and cognitive function. The company has primarily investigated treatments designed to support synaptic function and neuronal health.

Its lead research program has centered on bryostatin-1, a naturally derived compound being studied for its potential to activate protein kinase C epsilon and improve cognitive function in patients with Alzheimer’s disease. Synaptogenix has also explored potential applications of its technology in other neurological conditions, although its programs remain investigational and the company does not have an established portfolio of approved commercial products.

The company was formerly known as Neurotrope, Inc. and adopted the Synaptogenix name as it refined its focus on neurodegenerative disease research. Public information identifies Synaptogenix with the Nasdaq ticker SNPX; the ticker symbol TAOX appears to refer to a different issuer. Accordingly, the company and symbol provided should be independently verified before use.

View Synaptogenix Profile
Earnings Tools